Want to see QNCX full AI Analyst Report?
QNCX Stock Chart & Stats
$1.37
-$0.07(-3.61%)
At close: 4:00 PM EST
$1.37
-$0.07(-3.61%)
Day’s Range― - ―
52-Week Range$15.81 - $909.80
Previous CloseN/A
Volume30.57K
Average Volume (3M)1.53M
Market Cap
$14.83M
Enterprise Value-$12.73M
Total Cash (Recent Filing)$18.16M
Total Debt (Recent Filing)$406.00K
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Aug 11, 2026EPS Estimate
-9.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-124.60
Shares Outstanding815,037
10 Day Avg. Volume429,404
30 Day Avg. Volume1,533,817
Financial Highlights & Ratios
PEG Ratio-1.41
Price to Book (P/B)-93.98
Price to Sales (P/S)0.00
P/FCF Ratio-80.34
Enterprise Value/Market Cap-0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit179.28
Enterprise Value/Ebitda0.99
Forecast
1Y Price Target
$4.33Price Target Upside216.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-8.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage On Balance SheetVery low reported debt (TTM ~$0.3M; debt/equity ~0.02) gives a development-stage biotech structural financial flexibility. This reduces fixed-financing obligations, increasing optionality to fund R&D, pursue transactions, or weather funding gaps while clinical programs mature.
Orphai Acquisition And Committed FinancingAcquiring Orphai expands the pipeline into inhaled rapamycin with orphan indications and brings leadership into the board. The up-to-$187M private placement materially extends runway toward planned Phase 2 readouts, improving strategic optionality and supporting sustained program development.
Regained Nasdaq Continued-listing ComplianceRestoring compliance under an equity-based standard removed immediate delisting risk, preserving listing on the Nasdaq Global Market. This maintains access to public capital, institutional visibility and liquidity—important durable enablers for future financings and strategic partnerships.
Bears Say
Persistent Negative Cash FlowSustained operating and free cash flow deficits materially consume cash reserves and force reliance on new financing. Repeated negative cash generation limits runway, constrains strategic choices, and increases dilution risk if clinical milestones do not unlock alternative funding sources.
Pre-revenue With Sustained Operating LossesA pre-commercial profile with large recurring R&D and operating losses means company value depends entirely on future trial success and approvals. Without revenue, profitability is distant; continued high spend increases risk that programs or timelines must be altered if funding tightens.
Ongoing Market-value Listing UncertaintyWhile bid-price compliance was resolved, the outstanding market-value threshold creates a structural overhang. Continued uncertainty about meeting the $50M standard can impair fundraising terms and partner confidence and could rekindle delisting risk if equity value or book capital erodes.
Quince Therapeutics News
QNCX FAQ
What was Quince Therapeutics’s price range in the past 12 months?
Quince Therapeutics lowest stock price was $15.81 and its highest was $909.80 in the past 12 months.
What is Quince Therapeutics’s market cap?
Quince Therapeutics’s market cap is $14.83M.
When is Quince Therapeutics’s upcoming earnings report date?
Quince Therapeutics’s upcoming earnings report date is Aug 11, 2026 which is in 41 days.
How were Quince Therapeutics’s earnings last quarter?
Quince Therapeutics released its earnings results on May 19, 2026. The company reported $3.908 earnings per share for the quarter, beating the consensus estimate of -$1.3 by $5.208.
Is Quince Therapeutics overvalued?
According to Wall Street analysts Quince Therapeutics’s price is currently Undervalued.
Does Quince Therapeutics pay dividends?
Quince Therapeutics does not currently pay dividends.
What is Quince Therapeutics’s EPS estimate?
Quince Therapeutics’s EPS estimate is -9.4.
How many shares outstanding does Quince Therapeutics have?
Quince Therapeutics has 815,037 shares outstanding.
What happened to Quince Therapeutics’s price movement after its last earnings report?
Quince Therapeutics reported an EPS of $3.908 in its last earnings report, beating expectations of -$1.3. Following the earnings report the stock price went up 7.559%.
Which hedge fund is a major shareholder of Quince Therapeutics?
Currently, no hedge funds are holding shares in QNCX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Quince Therapeutics
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
QNCX Stock 12 Month Forecast
Average Price Target
$4.33
▲(216.30% Upside)
Technical Analysis
Ownership Overview
50.74% Insiders
0.02% Mutual Funds
0.39% Other Institutional Investors
48.57% Public Companies and
Individual Investors